• 1
    Mannino DM, Watt G, Hole D, Gillis G, Hart C, McConnachie A et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 62743.
  • 2
    Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease. Saskatchewan Canada. Ann Epidemiol 2006; 16: 6370.
  • 3
    Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med 2002; 166: 3339.
  • 4
    Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 151419.
  • 5
    Hunninghake D. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 449.
  • 6
    Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 54348.
  • 7
    Frishman WH, Furberg CD, Friedwald WT. Beta-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 1984; 310: 8307.
  • 8
    Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 17307.
  • 9
    Mangano DT, El L, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncadiac surgery. Multicentre study of peri-operative ischaemia research group. N Engl J Med 1996; 335: 171320.
  • 10
    Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Blissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98: 118491.
  • 11
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The 7th report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 21: 256072.
  • 12
    Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281: 192736.
  • 13
    Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 48997.
  • 14
    Everly MJ, Heaton PC, Cluxton RJ. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother 2004; 38: 28693.
  • 15
    Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta-1, beta-2 and beta-3 adrenoceptors. Br J Pharmacol 2005; 144: 31722.
  • 16
    Andrus MR, Loyed JV. Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity. Drugs Aging 2008; 25: 13144.
  • 17
    Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003; 97: 1094101.
  • 18
    Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 4: CD003566.
  • 19
    Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta-blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008; 63: 3015.
  • 20
    The National Collaborating Centre for Chronic Conditions. Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59(Suppl. 1): i1i232.
  • 21
    Van der Woude HJ, Zaagsma J, Postma DS, Winter TH, Van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD. A concern for non-selective beta-blockers. Chest 2005; 127: 81824.
  • 22
    Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007; 131(Suppl. 5): 4S42S.
  • 23
    Abdulla J, Kober L, Christensen E, Torp-Pedersen C. Effect of beta-blocker therapy on functional status in patients with heart failure–a meta-analysis. Eur J Heart Fail 2006; 8: 52231.
  • 24
    Butland RJ, Pang JA, Geddes DM Effect of beta-adrenergic blockade on hyperventilation and exercise tolerance in emphysema. J Appl Physiol 1983; 54: 136873.
  • 25
    Hancox RJ, Haney S. Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol 2006; 31: 18196.
  • 26
    Yan K, Salome C, Woolcock AJ. Rapid method for measurement of bronchial responsiveness. Thorax 1983; 38: 7605.
  • 27
    Hancox RJ, Aldridge RE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR et al. Tolerance to beta-agonists during acute bronchoconstriction. Eur Respir J 1999; 14: 2837.
  • 28
    Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47: 101924.
  • 29
    Chang CL, Cooray M, Mills G, Hancox RJ. Is Salamol less effective than Ventolin? A randomised, blinded, crossover study in New Zealand. NZ Med J 2007; 120: [cited 1 September 2008]. Available from: URL:
  • 30
    Kanner RE, Connett JE, Altose MD, Buist AS, Lee WW, Tashkin DP et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am J Respir Crit Care Med 1994; 150: 95661.
  • 31
    Singh SJ, Jones P, Evans R, Morgan M. The minimum clinically important improvement for the incremental shuttle walk test. Thorax 2008; 63: 7757. Epub: doi: 10.1136/thx.2007.081208
  • 32
    Faulhaber M, Flatz M, Burtscher M. Beta-blockers may provoke oxygen desaturation during submaximal exercise at moderate altitudes in elderly persons. High Alt Med Biol 2003; 4: 4758.
  • 33
    Feretti G, Licker MJ, Anchisi S, Moia C, Susta D, Morel DR. The effects of beta-1-adrenergic blockade on cardiovascular oxygen flow in normoxic and hypoic humans at exercise. Eur J Appl Physiol 2005; 95: 2509.
  • 34
    Wilkins BW, Pike TL, Martin EA, Curry TB, Ceridon ML, Joyner MJ. Exercise intensity-dependent contribution of beta-adrenergic receptor-mediated vasodilation in hypoxic humans. J Physiol 2008; 586: 1195205.